Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033364 | 0.88 | SLC6A9 (1.00) | SLC6A9CYP2D6CYP2C19SLC6A5 | |
| SCHEMBL3023311 | 0.86 | SLC6A9 (0.78) | SLC6A9CYP2D6CYP2C19SLC6A5 | |
| SCHEMBL3018519 | 0.85 | SLC6A9 (1.00) | SLC6A9CYP2D6CYP2C19SLC6A5 | |
| SCHEMBL3028377 | 0.84 | SLC6A9 (1.00) | SLC6A9CYP2D6CYP2C19SLC6A5 | |
| SCHEMBL3028410 | 0.84 | SLC6A9 (0.82) | SLC6A9CYP2D6CYP2C19SLC6A5 | |
| SCHEMBL3017885 | 0.84 | SLC6A9 (0.79) | SLC6A9CYP2D6CYP2C19SLC6A5 | |
| SCHEMBL3026714 | 0.84 | SLC6A9 (0.80) | SLC6A9CYP2D6CYP2C19SLC6A5 | |
| SCHEMBL7900806 | 0.84 | SLC6A9 (0.80) | SLC6A9CYP2D6CYP2C19SLC6A5 | |
| SCHEMBL7897260 | 0.84 | SLC6A9 (0.80) | SLC6A9CYP2D6CYP2C19SLC6A5 | |
| SCHEMBL3017365 | 0.84 | SLC6A9 (0.80) | SLC6A9CYP2D6CYP2C19SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067911-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158050-A1 | PIPERIDINE DERIVATIVES | GRIN1, GRIN2A, GRIN2C | SLC6A9 911/4885CYP2D6 595/4885CYP2C19 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.